Application Note No. 069 Mohamed Abdel-Rehim*, Karin A. Svensson, Yvonne Askemark, Karl-Johan Pettersson AstraZeneca Research and Development Söderä lje, Preclinical Development, DMPK/BC Development, P.O. Box 215, SE-151 85 Söderä lje, Sweden Received 7 November 2000; received in revised form 2…
Key words
cgc, plasma, ppx, aim, ptv, liner, ultrafiltration, metabolites, injecotr, directly, injecting, ultrafiltrate, variation, ropivacaine, seven